Evidence map›Paper›PMID 37560613›Full record

ArticleRespiratory medicine case reports2023

Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection.

Toru Hamada, Tomoya Katsuta, Kento Aibara, Shohei Nozu, Junya Nakamura, Haruka Kondo, Sayaka Tachibana, Koji Inoue, Norihiko Nakanishi, Tomonori Moritaka

Abstract readCase Reports
In one paragraph

Article in Respiratory medicine case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Duo biologic therapy using mepolizumab and omalizumab in refractory ABPA: two cases.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toru HamadaRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Tomoya KatsutaRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Kento AibaraRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Shohei NozuRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Junya NakamuraRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Haruka KondoRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Sayaka TachibanaRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Koji InoueRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Norihiko NakanishiRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.
Tomonori MoritakaRespiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction caused by the fungus

Indexed as

Allergic bronchial aspergillosisMepolizumabNumerous infectious complications

Identifiers

PMID37560613
PMCPMC10407267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.